| P50 | author | Michael J. Econs | Q40973951 |
| P2093 | author name string | Shoji Ichikawa | |
| | Amie K Gray | |
| | Anthony M Austin | |
| P2860 | cites work | Pathogenic role of Fgf23 in Hyp mice. | Q46921328 |
| | Genomic organization of the human PEX gene mutated in X-linked dominant hypophosphatemic rickets | Q48049188 |
| | The role of mutant UDP-N-acetyl-alpha-D-galactosamine-polypeptide N-acetylgalactosaminyltransferase 3 in regulating serum intact fibroblast growth factor 23 and matrix extracellular phosphoglycoprotein in heritable tumoral calcinosis. | Q52572405 |
| | Clinical variability of familial tumoral calcinosis caused by novel GALNT3 mutations | Q61831294 |
| | Osteomalacia in hyp mice is associated with abnormal phex expression and with altered bone matrix protein expression and deposition | Q73400284 |
| | Pex mRNA is localized in developing mouse osteoblasts and odontoblasts | Q74386168 |
| | Clinical usefulness of measurement of fibroblast growth factor 23 (FGF23) in hypophosphatemic patients: proposal of diagnostic criteria using FGF23 measurement | Q81038213 |
| | A novel recessive mutation in fibroblast growth factor-23 causes familial tumoral calcinosis | Q81353302 |
| | A gene (PEX) with homologies to endopeptidases is mutated in patients with X-linked hypophosphatemic rickets. The HYP Consortium | Q24308202 |
| | FGF-23 is a potent regulator of vitamin D metabolism and phosphate homeostasis | Q24319751 |
| | Polypeptide GalNAc-transferase T3 and familial tumoral calcinosis. Secretion of fibroblast growth factor 23 requires O-glycosylation | Q24321247 |
| | Treatment of X-linked hypophosphatemia with calcitriol and phosphate increases circulating fibroblast growth factor 23 concentrations | Q24595718 |
| | Tumoral calcinosis presenting with eyelid calcifications due to novel missense mutations in the glycosyl transferase domain of the GALNT3 gene | Q28260860 |
| | Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts | Q28510111 |
| | Circulating FGF-23 is regulated by 1alpha,25-dihydroxyvitamin D3 and phosphorus in vivo | Q28572995 |
| | Normalization of real-time quantitative reverse transcription-PCR data: a model-based variance estimation approach to identify genes suited for normalization, applied to bladder and colon cancer data sets | Q29615465 |
| | Distribution of mutations in the PEX gene in families with X-linked hypophosphataemic rickets (HYP). | Q30426917 |
| | Hyperostosis-hyperphosphatemia syndrome: a congenital disorder of O-glycosylation associated with augmented processing of fibroblast growth factor 23. | Q33264714 |
| | Isolated C-terminal tail of FGF23 alleviates hypophosphatemia by inhibiting FGF23-FGFR-Klotho complex formation | Q33591785 |
| | New intragenic deletions in the Phex gene clarify X-linked hypophosphatemia-related abnormalities in mice | Q33808604 |
| | Healing of bone disease in X-linked hypophosphatemic rickets/osteomalacia. Induction and maintenance with phosphorus and calcitriol | Q34629902 |
| | Mutational analysis of the PEX gene in patients with X-linked hypophosphatemic rickets | Q35238632 |
| | An ethyl-nitrosourea-induced point mutation in phex causes exon skipping, x-linked hypophosphatemia, and rickets. | Q35747726 |
| | A homozygous missense mutation in human KLOTHO causes severe tumoral calcinosis | Q35925637 |
| | Calcimimetics as an adjuvant treatment for familial hypophosphatemic rickets | Q36662050 |
| | Ablation of the Galnt3 gene leads to low-circulating intact fibroblast growth factor 23 (Fgf23) concentrations and hyperphosphatemia despite increased Fgf23 expression | Q37210780 |
| | Effects of hPTH(1-34) infusion on circulating serum phosphate, 1,25-dihydroxyvitamin D, and FGF23 levels in healthy men. | Q37345103 |
| | The regulation of parathyroid hormone secretion and synthesis | Q37821623 |
| | An FGF23 missense mutation causes familial tumoral calcinosis with hyperphosphatemia. | Q40482177 |
| | Developmental expression and tissue distribution of Phex protein: effect of the Hyp mutation and relationship to bone markers. | Q40862972 |
| | cDNA cloning of the murine Pex gene implicated in X-linked hypophosphatemia and evidence for expression in bone | Q42638660 |
| | Dietary and serum phosphorus regulate fibroblast growth factor 23 expression and 1,25-dihydroxyvitamin D metabolism in mice | Q44142771 |
| | Increased circulatory level of biologically active full-length FGF-23 in patients with hypophosphatemic rickets/osteomalacia | Q44203982 |
| | Fibroblast growth factor 23 in oncogenic osteomalacia and X-linked hypophosphatemia | Q44414604 |
| | Anti-FGF23 neutralizing antibodies show the physiological role and structural features of FGF23. | Q44465622 |
| | A novel homozygous missense mutation in FGF23 causes Familial Tumoral Calcinosis associated with disseminated visceral calcification | Q45345392 |
| | A novel Phex mutation in a new mouse model of hypophosphatemic rickets | Q46290971 |
| | Vitamin D receptor-independent FGF23 actions in regulating phosphate and vitamin D metabolism | Q46585085 |
| | A novel mutation in fibroblast growth factor 23 gene as a cause of tumoral calcinosis | Q46609225 |
| P433 | issue | 2 | |
| P921 | main subject | murine model | Q122890741 |
| P304 | page(s) | 453-460 | |
| P577 | publication date | 2012-02-01 | |
| P1433 | published in | Journal of Bone and Mineral Research | Q15750941 |
| P1476 | title | A Phex mutation in a murine model of X-linked hypophosphatemia alters phosphate responsiveness of bone cells | |
| P478 | volume | 27 | |